


## Back to Overview (https://my.ean.org/s/abstracts)



Abstract FAQs

Withdraw

## Information

ss Budapest 2023 (/s/event/a1M3Y000006n1xIUAA/congress-budapest-2023)

Stage

Submitted

Type

Oral

Status Pending

Abstract Topic

MS and related disorders

Date Submitted

26/01/2023 11:28

## ∨ Body

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

In the ASCLEPIOS I/II core studies, ofatumumab delayed disability accrual compared with teriflunomide. Progression independent of relapse activity (PIRA) was the main contributor to overall 3-/6-month confirmed disability worsening (3/6mCDW). We assessed CDW, PIRA, relapse-associated worsening (RAW), and brain volume change (BVC) in relapsing multiple sclerosis patients receiving of atumumab for up to 5 years.

Results are presented in this abstract for up to 4 years (ASCLEPIOS + ALITHIOS open-label extension) in patients on continuous ofatumumab and those switched from teriflunomide in the extension (full analysis set); 5-year data will be available at congress. CDW, PIRA (CDW events without prior confirmed relapses), RAW (event onset <90 days from a relapse), percent BVC (PBVC) and annualized rates of BVC (ABVC) were assessed.

Of 1882 patients randomised in ASCLEPIOS I/II, 1367 entered ALITHIOS (Figure 1). Most patients were free from 3/6mCDW events. Up to 4 years (cut off:25-Sep-2021) 12.6% and 15.9% patients had 6mCDW in the continuous and switch groups, respectively. In the continuous group, the 6mPIRA Kaplan-Meier cumulative event rate (KM-CER) remained low (11.0%) and 6mPIRA accounted for 72.3% patients with 6mCDW; 6mRAW (KM-CER: 3.5%) accounted for only 25.2% patients (Table 1). At week 240, overall mean PBVC remained low (continuous/switch: -1.42%/-1.62%). ABVC for continuous of atumumab also remained low(core: -0.34%/year; extension: -0.28%/year). In the switch group, ABVC was -0.42%/year(core) and -0.29%/year(extension).

With longer-term of atumumab treatment, disability worsening was predominantly PIRA, the annual rate of BVC remained low, and most patients remained free from disease progression. Outcomes favoured early initiation with ofatumumab.

Disclosure

The study was supported by Novartis Pharma AG, Switzerland. The detailed author disclosures will be provided in the subsequent presentation.

H. Wiendl 1, J. Cohen 2, S. Hauser 3, E. Fox 4, R. Zielman 5, J. Xi 6, A. Azmon 7, A. Das Gupta 8, G. Mavrikis Cox 9, D. Robertson 10, L. Kappos 11; 1 University of Muenster, Muenster, Germany, <sup>2</sup> Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, <sup>3</sup> UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA;, 4 Central Texas Neurology Consultants, Round Rock, TX, USA, <sup>5</sup> Novartis Pharma B.V., Amsterdam, The Netherlands, <sup>6</sup> China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, <sup>7</sup> Novartis Pharma A.G., Basel, Switzerland, <sup>8</sup> Novartis Healthcare Pvt. Ltd., Hyderabad, India, <sup>9</sup> Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>10</sup> Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, 11 Research Center for Clinical Neuroimmunology and Neuroscience Basel and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

